-Advertisement-
-Advertisement-
FDA Alerts

FDA approves Evkeeza for young children with ultra-rare form of high cholesterol
The U.S. Food and Drug Administration has extended the approval of evinacumab-dgnb (Evkeeza; Regeneron) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), according to a press release. Evinacumab was approved in February 2021 as an adjunct to other lipid-lowering...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 MedJournal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved